The goal of our proposed research is to develop a Brucella vaccine that is safe for human use. Our approach has explored the use of live attenuated vaccines, since subunit vaccines have shown little real promise. Our approach combines the optimal features of a deliverable vaccine that is safe, free of side effects and efficacious in humans with enhanced immune stimulation through microencapsulation. The competitive advantages and innovations of our approach are: (1) use of a highly attenuated, safe, gene knockout, live B. melitensis mutants;(2) manufacturing with unique disposable closed system technologies, and (3) oral/intranasal delivery in a novel microencapsulation-mediated controlled release formula to optimally provide the long term mucosal immunostimulation required for protective immunity. Based upon our preliminary data, we postulate that our vaccine delivery system will ultimately be storage stable, administered orally or intranasally, and generally applicable to a number of select agents. We present a welldesigned 5-year timeline with milestones for developing GMP-produced vaccine for vaccination-aerosol challenge studies in non-human primates as a pathway to a clinical Investigational New Drug studies on the path to FDA Biological License Application. The development of the proposed product takes full advantage of a strong team and ongoing research with bacterial genetics and testing in multiple animal models coupled with novel manufacturing and microencapsulation technologies that balance product safety, stability, costs, and potency.
No human brucellosis vaccine is available despite the continued presence of the organism in 86 countries in which tens of thousands of humans are treated for brucellosis annually. Although the ongoing threat to the US has been greatly reduced, the potential threat to the United States remains high and retains both public health and economic impact.
|Paterson, Andrew S; Raja, Balakrishnan; Garvey, Gavin et al. (2014) Persistent luminescence strontium aluminate nanoparticles as reporters in lateral flow assays. Anal Chem 86:9481-8|
|Santiago, Felix W; Covaleda, Lina M; Sanchez-Aparicio, Maria T et al. (2014) Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic structures correlates with the inhibition of type I interferon responses. J Virol 88:4572-85|
|Pflughoeft, Kathryn J; Swick, Michelle C; Engler, David A et al. (2014) Modulation of the Bacillus anthracis secretome by the immune inhibitor A1 protease. J Bacteriol 196:424-35|
|Lavinder, Jason J; Wine, Yariv; Giesecke, Claudia et al. (2014) Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A 111:2259-64|
|Valbuena, Gustavo; Halliday, Hailey; Borisevich, Viktoriya et al. (2014) A human lung xenograft mouse model of Nipah virus infection. PLoS Pathog 10:e1004063|
|Nieves, Wildaliz; Petersen, Hailey; Judy, Barbara M et al. (2014) A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol 21:747-54|
|Gardner, Christina L; Hritz, Jozef; Sun, Chengqun et al. (2014) Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719|
|Litvinov, Julia; Hagström, Anna E V; Lopez, Yubitza et al. (2014) Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation. Biotechnol Lett 36:1863-8|
|Caro-Gomez, Erika; Gazi, Michal; Goez, Yenny et al. (2014) Discovery of novel cross-protective Rickettsia prowazekii T-cell antigens using a combined reverse vaccinology and in vivo screening approach. Vaccine 32:4968-76|
|Georgiou, George; Ippolito, Gregory C; Beausang, John et al. (2014) The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol 32:158-68|
Showing the most recent 10 out of 303 publications